Keytruda (Pembrolizumab) and Tecentriq (Atezolizumab) from global pharmaceutical companies are challenging to expand their benefits as primary drugs for lung cancer.

According to the pharmaceutical industry and the medical community on the 10th, the HIRA's Cancer Drugs Benefit Apparel Committee will discuss ways to expand the benefits of the two drugs at its fifth meeting in 2021.

In the case of MSD Korea's Keytruda, five benefit expansion proposals were proposed at the fourth Cancer Drugs Benefit Appraisal Committee meeting in May, and two of them were passed.

Benefit needs for urinary epithelial cancer secondary therapy and Hodgkin's lymphoma non-responsive secondary and